DexCom specializes in continuous glucose monitoring systems, primarily focusing on individuals managing diabetes. Its innovative CGM systems, like the G6 and the newer G7, offer real-time glucose ...

DexCom projects 2025 revenue of $4.6 billion, representing 14% growth. This forecast assumes strong demand for CGM systems, expanded reimbursement coverage, and a second-half launch of a 15-day G7 ...

She notes that DexCom is positioned for long-term growth, supported by its expanding product lineup, including G7, Dexcom One, and Stelo, and opportunities to reach new patient groups. However ...

Q4 2024 Earnings Call Transcript February 13, 2025 DexCom, Inc. misses on earnings expectations. Reported EPS is $0.45 EPS, expectations were $0.4792. Operator: Thank you for standing by. My name is ...

With the salesforce ramping up and regulatory approval of the 15-day G7 sensor expected this year ... largest pharmacy benefit managers now cover Dexcom CGMs for Type 2, which translates into ...

My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Dexcom Inc. fourth quarter 2024 earnings release conference call. All lines ...